Michael J. Overman, MD

Articles

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Dr. Overman on Ongoing Research With Immunotherapy in Microsatellite Stable CRC

May 6th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. Overman on Choosing Between Regorafenib and TAS-102 in CRC

March 28th 2020

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Dr. Overman on Second-Line Therapy Options for Colorectal Cancer

March 23rd 2020

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

Dr. Overman on Investigational Targeted Therapies in mCRC

March 11th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).

Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC

April 26th 2019

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

Dr. Overman on Unmet Needs With Immunotherapy in mCRC

April 19th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses unmet needs with immunotherapy in metastatic colorectal cancer.

Dr. Overman Discusses ReDOS Study in mCRC

February 26th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.

Dr. Overman Discusses Progress With Immunotherapy in GI Cancer

January 12th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses progress made with immunotherapy agents in gastrointestinal (GI) cancer.

Dr. Overman on Next Steps With Immunotherapy in mCRC

December 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

x